Table 5. Relevant clinical reports studying effects of regadenoson in patients with renal impairment.

ESRD: End-stage renal disease; CKD: Chronic kidney disease; HR: Heart rate; SBP: Systolic blood pressure; GFR: Glomerular filtration rate

* No serious adverse events or deaths were reported 24 hours post-dose

 

Authors	Design	Sample size	Primary outcomes	Results
Aljaroudi et al. [32]	Observational, retrospective study.	277 patients with ESRD, 134 patients with normal kidney function	Change in HR change in SBP	No significant difference
Doukky et al. [33]	Observational, retrospective study	146 ESRD patients, 97 patients GFR ≥ 30	Regandonson adverse effects ST-segment deviation, arrhythmias, AV block, hypotension	No significant difference
Ananthasubramaniam et al. [34]	Randomized, double-blinded, placebo-controlled study.	432 subjects with stage 3 CKD (regadenoson n = 287; placebo n = 145), and 72 subjects with stage 4 CKD (regadenoson n = 47; placebo n = 25)	Regandonson adverse events (24 hours post-dose)	The incidence of adverse events was higher in the regadenoson group compared to the placebo